Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1772192
PUBLISHER: Grand View Research | PRODUCT CODE: 1772192
Japan Genome Editing Market Size, Share & Trends Analysis Report By Technology, By Delivery Method, By Application, By Mode, By End Use, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 110 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Japan Genome Editing Market Growth & Trends:
The Japan genome editing market size is projected to reach USD 1.45 billion by 2033, growing at a CAGR of 17.97% from 2025 to 2033, according to a new report by Grand View Research, Inc. The Japan genome editing market is witnessing robust expansion, propelled by increasing investment in precision medicine, regenerative therapies, and agricultural biotechnology. The growing focus on next-generation therapeutics, particularly gene therapies, rare disease treatments, and personalized oncology solutions, fuels demand for advanced genome editing technologies such as CRISPR-Cas9, TALENs, and base editors. Regulatory encouragement and supportive government initiatives, including funding for biotech innovation and streamlining of clinical approval processes, further accelerate market momentum.
A strong academic and research infrastructure and the presence of globally recognized institutions underpin innovation and collaboration across sectors. Pharmaceutical companies, biotech startups, and educational consortia are increasingly converging to translate gene editing breakthroughs into viable clinical and commercial applications. Japan's aging population and rising incidence of chronic genetic disorders are also driving urgency around genome-targeted interventions, catalyzing demand for safe, effective, and scalable editing platforms.
Technological advancements in delivery systems, precision targeting, and off-target risk mitigation are expanding genome editing's therapeutic applicability. Integration with digital tools and AI-driven bioinformatics platforms is improving target discovery, optimizing design workflows, and accelerating preclinical development. In agriculture and food biotechnology, gene editing is applied to develop disease-resistant, high-yield crops, aligning with national food security and sustainability goals.
With cross-sector partnerships, increased R&D activity, and supportive policy frameworks, the Japan genome editing market is well-positioned to play a leading role in shaping the future of precision biotechnology. Strategic alliances, localized manufacturing, and a growing IP portfolio reinforce Japan's position as a key hub for genome editing innovation in therapeutic and non-therapeutic applications.
Japan Genome Editing Market Report Highlights:
- By technology, CRISPR/Cas9 dominated the Japan genome editing market with a market share of 44.14% in 2024. This dominance stems from CRISPR/Cas9's superior efficiency, precision, and cost-effectiveness in targeted genome modifications. Its widespread adoption across research institutes, biotech startups, and pharmaceutical companies reflects its ability to accelerate functional genomics studies, therapeutic development, and agricultural innovation. The relatively easier design and scalability of CRISPR/Cas9 tools make them the preferred choice for both in vitro and in vivo applications.
- By delivery method, in vivo genome editing led the market with a market share of 50.63% in 2024, driven by rising investments in gene therapy and regenerative medicine, especially for treating inherited diseases and cancers. Japan's advanced healthcare infrastructure and focus on curative therapies have fueled the development of novel delivery platforms, such as lipid nanoparticles and adeno-associated viral vectors (AAVs), enabling more effective gene transfer in living organisms. The ability to directly edit genes within the patient offers transformative potential and continues to attract clinical trial activity and investment.
- By application, genetic engineering emerged as the leading segment, with a market share of 73.16% in 2024, contributing the highest revenue share. The segment's growth is driven by Japan's commitment to disease modeling, therapeutic discovery, and functional genomics research. Genetic engineering is widely used across academia and industry to develop customized cell lines, engineer model organisms, and advance gene therapy pipelines. It also plays a crucial role in precision breeding for agriculture and aquaculture, which are strategic sectors in Japan's biotech innovation agenda.
- By mode, the contract segment held the largest share of 66.77% in 2024, as outsourcing genome editing services becomes increasingly common among biotech startups and research institutions. Contract service providers offer specialized expertise, infrastructure, and regulatory support, allowing innovators to reduce time-to-market and control development costs. Japan's strong contract research and manufacturing organization ecosystem supports gene editing across preclinical, clinical, and commercial phases.
- By end use, biotechnology and pharmaceutical companies dominated the Japan genome editing market with a share of 49.66% in 2024. These companies leverage genome editing to accelerate drug discovery, develop gene and cell therapies, and explore novel treatment modalities for complex diseases. With robust R&D pipelines and increasing government incentives, these end users are at the forefront of innovation. Collaborations with academic institutions and global biotech firms further strengthen their position, making them central players in the commercial Application of genome editing technologies.
- In January 2025, Takara?Bio USA Holdings, Inc. completed the acquisition of California?based Curio Bioscience, integrating its Trekker and Seeker spatial?biology platforms into its U.S. single?cell omics portfolio.
Product Code: GVR-4-68040-648-1
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Technology Segment
- 1.2.2. Method Segment
- 1.2.3. Application Segment
- 1.2.4. Mode Segment
- 1.2.5. End-use Segment
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Japan Genome Editing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Japan Genome Editing Market: Technology Business Analysis
- 4.1. Technology Segment Dashboard
- 4.2. Japan Genome Editing Market Technology Movement Analysis
- 4.3. Japan Genome Editing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 4.4. CRISPR/Cas9
- 4.4.1. CRISPR/Cas9 market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. TALENs/MegaTALs
- 4.5.1. TALENS/MegaTALs market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. ZFN
- 4.6.1. ZFN market estimates and forecasts 2021 to 2033 (USD Million)
- 4.7. Meganucleases
- 4.7.1. Meganucleases market estimates and forecasts 2021 to 2033 (USD Million)
- 4.8. Others
- 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Japan Genome Editing Market: Delivery Method Business Analysis
- 5.1. Delivery Method Segment Dashboard
- 5.2. Japan Genome Editing Market Delivery Method Movement Analysis
- 5.3. Japan Genome Editing Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
- 5.4. Ex-vivo
- 5.4.1. Ex-vivo market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. In- vivo
- 5.5.1. In-Vivo market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Japan Genome Editing Market: Application Business Analysis
- 6.1. Application Segment Dashboard
- 6.2. Japan Genome Editing Market Application Movement Analysis
- 6.3. Japan Genome Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Genetic Engineering
- 6.4.1. Genetic Engineering market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.2. Cell line engineering
- 6.4.2.1. Cell line engineering market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.3. Animal genetic engineering
- 6.4.3.1. Animal genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.4. Plant genetic engineering
- 6.4.4.1. Plant genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.5. Others
- 6.4.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Clinical Applications
- 6.5.1. Clinical Applications market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.2. Therapy Development
- 6.5.2.1. Therapy Development market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.3. Diagnostics Development
- 6.5.3.1. Diagnostics Development market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Japan Genome Editing Market: Mode Business Analysis
- 7.1. Mode Segment Dashboard
- 7.2. Japan Genome Editing Market Mode Movement Analysis
- 7.3. Japan Genome Editing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
- 7.4. Contract
- 7.4.1. Contract market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. In- house
- 7.5.1. In-house market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Japan Genome Editing Market: End Use Estimates & Trend Analysis
- 8.1. End Use Segment Dashboard
- 8.2. Japan Genome Editing Market End Use Movement Analysis
- 8.3. Japan Genome Editing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 8.4. Biotechnology & Pharmaceutical Companies
- 8.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Academic & Research Institutes
- 8.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6. Contract Research Organizations
- 8.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2024
- 9.4. Company Profiles/Listing
- 9.4.1. Merck KGaA
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. Takara Bio Inc.
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. Revvity, Inc.
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. Danaher Corporation
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. GenScript
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. New England Biolabs
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. Lonza
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Thermo Fisher Scientific, Inc.
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. Charles River Laboratories
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Eurofins Scientific
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
- 9.4.1. Merck KGaA
Product Code: GVR-4-68040-648-1
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 Regulatory Framework
- Table 4 Japan Genome editing Market, By technology, 2021 - 2033 (USD Million)
- Table 5 Japan Genome editing Market, By delivery method, 2021 - 2033 (USD Million)
- Table 6 Japan Genome editing Market, By application, 2021 - 2033 (USD Million)
- Table 7 Japan Genome editing Market, By mode, 2021 - 2033 (USD Million)
- Table 8 Japan Genome editing Market, By end use, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Japan genome editing market segmentation
- Fig. 2 Information procurement
- Fig. 3 Data analysis models
- Fig. 4 Market formulation and validation
- Fig. 5 Data validating & publishing
- Fig. 6 Market research process
- Fig. 7 Information procurement
- Fig. 8 Primary research
- Fig. 9 Market snapshot
- Fig. 10 Segment snapshot
- Fig. 11 Competitive landscape snapshot
- Fig. 12 Japan genome editing market: Technology outlook key takeaways
- Fig. 13 Japan genome editing market: Technology movement analysis
- Fig. 14 Japan CRISPR/Cas9 market, 2021 - 2033 (USD Million)
- Fig. 15 Japan TALENs/MegaTALs market, 2021 - 2033 (USD Million)
- Fig. 16 Japan ZFN market, 2021 - 2033 (USD Million)
- Fig. 17 Japan meganucleases market, 2021 - 2033 (USD Million)
- Fig. 18 Japan others market, 2021 - 2033 (USD Million)
- Fig. 19 Japan genome editing market: Delivery Method outlook and key takeaways
- Fig. 20 Japan genome editing market: Delivery Method movement analysis
- Fig. 21 Japan ex- vivo market, 2021 - 2033 (USD Million)
- Fig. 22 Japan in- vivo market, 2021 - 2033 (USD Million)
- Fig. 23 Japan genome editing market: Application outlook and key takeaways
- Fig. 24 Japan genome editing market: Application movement analysis
- Fig. 25 Japan genetic engineering market, 2021 - 2033 (USD Million)
- Fig. 26 Japan cell line engineering market, 2021 - 2033 (USD Million)
- Fig. 27 Japan animal engineering market, 2021 - 2033 (USD Million)
- Fig. 28 Japan plant engineering market, 2021 - 2033 (USD Million)
- Fig. 29 Japan others market, 2021 - 2033 (USD Million)
- Fig. 30 Japan clinical applications market, 2021 - 2033 (USD Million)
- Fig. 31 Japan diagnostics development market, 2021 - 2033 (USD Million)
- Fig. 32 Japan therapy development market, 2021 - 2033 (USD Million)
- Fig. 33 Japan genome editing market: Mode outlook and key takeaways
- Fig. 34 Japan genome editing market: Mode movement analysis
- Fig. 35 Japan contract market, 2021 - 2033 (USD Million)
- Fig. 36 Japan in- house market, 2021 - 2033 (USD Million)
- Fig. 37 Japan genome editing market: End use outlook and key takeaways
- Fig. 38 Japan genome editing market: End use movement analysis
- Fig. 39 Japan biotechnology & pharmaceutical companies market, 2021 - 2033 (USD Million)
- Fig. 40 Japan academic & research institutes market, 2021 - 2033 (USD Million)
- Fig. 41 Japan contract research organizations market, 2021 - 2033 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.